Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

October 01, 2018 11:39 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Founder Dr. James P. Allison Jointly Awarded 2018 Nobel Prize in Physiology or Medicine for the Discovery of Cancer Therapy by Inhibition of Negative Immune Regulation

CAMBRIDGE, Mass., Oct. 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
September 26, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present at the 2018 Cantor Global Healthcare Conference

CAMBRIDGE, Mass., Sept. 26, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
August 29, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present at Upcoming Investor Conferences in September

CAMBRIDGE, Mass., Aug. 29, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
August 09, 2018 06:30 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Reports Second Quarter 2018 Financial Results

- Initiated enrollment in dose escalation cohorts of Phase 1/2 ICONIC trial of JTX-2011, in combination with ipilimumab and in combination with pembrolizumab - - Presented preliminary efficacy data...
August 02, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Announce Second Quarter 2018 Financial Results and Host Conference Call on Thursday, August 9, 2018

CAMBRIDGE, Mass., Aug. 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ: JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
June 02, 2018 16:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Presents Preliminary Efficacy Data from Ongoing Phase 1/2 ICONIC Trial of JTX-2011 in Patients with Advanced Cancers

CAMBRIDGE, Mass., June 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and...
May 16, 2018 17:01 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present Data from Ongoing ICONIC Trial of JTX-2011 at the 2018 American Society of Clinical Oncology Annual Meeting

ICONIC Target Enrollment Met Across Four Combination Cohorts Company to Host Investor Event and Live Webcast on Monday, June 4 CAMBRIDGE, Mass., May 16, 2018 (GLOBE NEWSWIRE) -- Jounce...
May 09, 2018 06:30 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics Reports First Quarter 2018 Financial Results

- Preliminary efficacy data from Phase 1/2 ICONIC trial to be presented as an oral presentation at the 2018 ASCO Annual Meeting - - Company to host conference call and webcast today at 8:00 AM ET - ...
May 02, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Announce First Quarter 2018 Financial Results and Host Conference Call on Wednesday, May 9, 2018

CAMBRIDGE, Mass., May 02, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...
May 01, 2018 08:00 ET | Source: Jounce Therapeutics, Inc.

Jounce Therapeutics to Present at Deutsche Bank 43rd Annual Health Care Conference

CAMBRIDGE, Mass., May 01, 2018 (GLOBE NEWSWIRE) -- Jounce Therapeutics, Inc. (NASDAQ:JNCE), a clinical stage company focused on the discovery and development of novel cancer immunotherapies and...